Q32 Bio, Inc. (QTTB)
7.77
-0.24
(-3.00%)
USD |
NASDAQ |
Oct 15, 16:00
7.80
+0.03
(+0.39%)
After-Hours: 20:00
Q32 Bio Research and Development Expense (Quarterly) : 4.259M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 4.259M |
| March 31, 2026 | 3.218M |
| December 31, 2025 | 3.315M |
| September 30, 2025 | 3.555M |
| June 30, 2025 | 5.161M |
| March 31, 2025 | 7.124M |
| December 31, 2024 | 10.54M |
| September 30, 2024 | 14.35M |
| June 30, 2024 | 13.41M |
| March 31, 2024 | 9.841M |
| December 31, 2023 | 8.339M |
| September 30, 2023 | 7.463M |
| June 30, 2023 | 8.017M |
| March 31, 2023 | 7.91M |
| December 31, 2022 | 27.15M |
| September 30, 2022 | 25.85M |
| June 30, 2022 | 21.08M |
| March 31, 2022 | 24.27M |
| Date | Value |
|---|---|
| December 31, 2021 | 23.65M |
| September 30, 2021 | 23.99M |
| June 30, 2021 | 23.70M |
| March 31, 2021 | 21.76M |
| December 31, 2020 | 23.20M |
| September 30, 2020 | 20.42M |
| June 30, 2020 | 27.47M |
| March 31, 2020 | 29.31M |
| December 31, 2019 | 20.34M |
| September 30, 2019 | 25.69M |
| June 30, 2019 | 22.83M |
| March 31, 2019 | 20.54M |
| December 31, 2018 | 16.28M |
| September 30, 2018 | 13.39M |
| June 30, 2018 | 10.29M |
| March 31, 2018 | 7.997M |
| December 31, 2017 | 9.576M |
| September 30, 2017 | 4.947M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Intellia Therapeutics, Inc. | 80.50M |
| Beam Therapeutics, Inc. | 95.10M |
| Prime Medicine, Inc. | 33.40M |
| Prelude Therapeutics, Inc. | 16.13M |
| Twist Bioscience Corp. | 18.02M |